KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

[GEM plus CDDP Combination Therapy for Unresectable Biliary Tract Cancer-A Single Institution Experience].

Masato Muneta, Yoshiaki Ohmura, Yutaka Takeda, Yoshiteru Katsura, Go Shinke, Mitsuru Kinoshita, Shu Aoyama, Yukari Kihara, Shinsuke Katsuyama, Ryo Ikeshima, Masayuki Hiraki, Keijiro Sugimura, Toru Masuzawa, Taishi Hata, Kohei Murata

Gan To Kagaku Ryoho 50(2) 239-241

PMID36807184
PMCID-
DOI-
发表日期2023-02-22
入排依据:The publication is a primary result report of a human, randomized, Phase III oncology trial with a drug intervention. However, it does not include a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) as required by the cohort definition. The primary efficacy measure reported is disease control rate, which is a categorical, non-time-to-event outcome.
摘要

摘要

BACKGROUND: Since a randomized phase Ⅲ trial conducted in the UK in 2009 showed the superiority of gemcitabine (GEM)plus cisplatin(CDDP)combination therapy over GEM monotherapy, GEM plus CDDP combination therapy has been first-line chemotherapy for unresectable biliary tract cancer. METHODS: GEM plus CDDP combination therapy was administered to 29 patients with unresectable biliary tract cancer from 2016 to 2021. RESULTS: The mean age was 71.9 years, male/ female 19/10. The target of chemotherapy was below, local progression was 3 cases, first distant metastasis 7 cases, metastatic recurrence 19 cases. The type of cancer was below, intrahepatic bile duct carcinoma was 8 cases, hepatic hilar bile duct carcinoma 6 cases, gallbladder carcinoma 5 cases, cystic duct carcinoma 1 case, distal bile duct carcinoma 6 cases, and papilla Vater's cancer 3 cases. The dosing period was 23.1 weeks(range 2-52 weeks). The relative dose intensities of GEM and CDDP were 73.7% and 75.1%. The adverse events were below, the hematological toxicities of Grade 3 or higher were neutropenia(65.5%), leukopenia(3.4%), and thrombocytopenia(10.3%). Non-hematological toxicities of Grade 2 or higher were fatigue(13.7%)and skin rash(6.9%). There was no interstitial pneumonia. The disease control rate was 66.7 %(complete response, n=0; partial response, n=6; stable disease, n=10; progressive disease, n=8). CONCLUSION: GEM plus CDDP combination therapy was safe to perform and was an effective treatment for unresectable biliary tract cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。